AChE inhibitors reduce AChE activity and maintain or increase ACh levels, which are typically deficient in Alzheimer’s disease (AD), and thus, enhance cholinergic transmission in brain [2,3]. The gene discussed is ACHE; the disease is Alzheimer disease.